1

- 1 **TITLE**: Development of the ADFICE_IT clinical decision support system to assist
- 2 deprescribing of fall-risk increasing drugs: A user-centered design approach
- 3

4 FULL NAMES AND INSTITUTIONAL ADDRESSES FOR ALL AUTHORS:

- 5 Sara S. Groos (1,2)
- 6 Kelly K. de Wildt (1,2)
- 7 Bob van de Loo (1,2,3)
- 8 Annemiek J. Linn (4)
- 9 Stephanie Medlock (2,5)
- 10 Kendrick M. Shaw (6, 7)
- 11 Eric K. Herman (8)
- 12 Lotta J. Seppala (1,2)
- 13 Kim J. Ploegmakers (1,2)
- 14 Natasja M. van Schoor (2,3)
- 15 Julia C. M. van Weert (4)
- 16 Nathalie van der Velde* (1,2)
- 17 ***CORRESPONDING AUTHOR**: s.s.groos@amsterdamumc.nl
- 18

19 Affiliations

- 20 (1) Amsterdam UMC location University of Amsterdam, Internal Medicine, Section of Geriatric
- 21 Medicine, Meibergdreef 9, Amsterdam, the Netherlands
- 22 (2) Amsterdam Public Health research institute, Amsterdam, the Netherlands

- 23 (3) Amsterdam UMC location Vrije Universiteit Amsterdam, Epidemiology and Data
- 24 Science, De Boelelaan 1117, Amsterdam, the Netherlands
- 25 (4) Amsterdam School of Communication Research/ASCoR, University of Amsterdam,
- 26 Amsterdam, the Netherlands
- 27 (5) Amsterdam UMC location University of Amsterdam, Department of Medical
- 28 Informatics, Meibergdreef 9, Amsterdam, the Netherlands
- 29 (6) Massachusetts General Hospital, Department of Anesthesia, Critical Care and Pain Medicine,
- 30 55 Fruit Street, Boston MA, United States of America
- 31 (7) Harvard Medical School, 25 Shattuck Street, Boston MA, United States of America
- 32 (8) Foundation for Public Code, Keizersgracht 617, Amsterdam, The Netherlands
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45

3

46 Abstract

47	Introduction: Deprescribing fall-risk increasing drugs (FRIDs) is a promising intervention
48	for reducing the risk of falling in older adults. Applying appropriate deprescribing in practice can
49	be difficult due to the outcome uncertainties associated with stopping the use of FRIDs. The
50	ADFICE_IT study addresses this complexity with a clinical decision support system (CDSS) that
51	facilitates optimum deprescribing of FRIDs through use of a fall-risk prediction model,
52	aggregation of deprescribing guidelines, and joint medication management. The development
53	process of the CDSS is described in this paper.
54	Methods: Development followed a user-centered design approach in which users and experts
55	were involved throughout each phase. In phase I, a prototype of the CDSS was developed which
56	involved a scoping and systematic literature review, European survey ($n = 581$), and semi-
57	structured interviews with physicians ($n = 19$), as well as the aggregation and testing of
58	deprescribing guidelines and the development of the fall-risk prediction model. In phase II, the
59	feasibility of the CDSS was tested by means of two usability testing rounds with end users ($n =$
60	11).
61	Results: The final CDSS consists of five web pages. A connection between the Electronic
62	Health Record allows for the retrieval of patient data into the CDSS. Key design requirements
63	for the CDSS include easy-to-use features for fast-paced clinical practice environments,
64	actionable deprescribing recommendations, information transparency, and visualization of the
65	patient's fall-risk estimation. Key elements for the software include a modular architecture, open
66	source, and good security.

67 Conclusion: The ADFICE_IT CDSS supports physicians in deprescribing FRIDs optimally
68 to prevent falls in older patients. Due to continuous user and expert involvement, each new

69	feedback round lea	l to an improved	l version of t	he system.	Currently,	a multicenter,	cluster-

- 70 randomized controlled trial with process evaluation at hospitals in the Netherlands is being
- 71 conducted to test the effect of the CDSS on falls.

73	Keywords

- 74 Clinical decision support system, Falls prevention, Medication deprescribing, User-computer
- 75 interface, Share decision-making, User-centered design, Risk communication

5

92 Introduction

93 Falls and fall-related injuries among older adults are a growing major public health problem [1]. 94 In 2017, 11.7 million older adults in Western Europe requested medical treatment for an injury, 95 of which 8.4 million were fall-related [2]. Injurious falls may result in admission to long term 96 care, loss of independence, reduced mobility, fear of falling, and social isolation, significantly 97 reducing the quality of life for older adults [3-5]. As a result, falls place a significant financial 98 burden on healthcare systems. In Western countries, it is estimated that up to 1.5 percent of the 99 total healthcare expenditures are attributed to fall-related medical care costs [3, 6]. 100 A prominent risk factor for falls in older adults is the use of certain medication classes 101 known as fall-risk increasing drugs (FRIDs). The use or combined use of FRIDs, such as 102 psychotropics and cardiovascular drugs, is associated with adverse effects including orthostatic 103 hypertension, syncope, sedation, and dizziness that can cause accidental falls in older adults [7-104 10]. Therefore, appropriate deprescribing of FRIDs is recommended for lowering an older 105 adult's risk of incurring a medication-related fall [11]. Nevertheless, previous studies suggest 106 that deprescribing approaches have yet to be optimized, as current approaches do not sufficiently address the complexity of FRIDs deprescribing for physicians [12, 13]. 107 108 Deprescribing FRIDs is highly complex due to healthcare professional, patient, cultural 109 and organizational reasons. For example first, physicians themselves may perceive difficulties 110 with *which*, *how* and *when* a FRID or combination of FRIDs should be safely deprescribed. This 111 results in the reluctancy to deprescribe, a phenomena that is especially prominent in the 112 treatment of older patients with polypharmacy and multimorbidity [14, 15]. Second, the unique 113 risk profiles of these patients can greatly increase the complexity of FRIDs deprescribing due to

the weighing of competing clinical practice guidelines [15, 16]. As a result, physicians may have

6

115 a tendency to overestimate the expected benefits of medications (i.e., effective treatment of the 116 chronic condition) and underestimate the potential harms (i.e., an injurious fall) in these patients 117 [17]. Third, physicians may also experience deprescribing reluctance from the patient. Research 118 suggests that low medication-related knowledge in geriatric patients, such as the management of 119 medications, can negatively influence appropriate deprescribing [18]. 120 One way to better support physicians in the deprescribing of FRIDs is by means of a 121 clinical decision support system (CDSS). Such a system has the ability to link individual patient 122 characteristics to a computerized clinical knowledge base which uses information from 123 guidelines to generate patient-specific recommendations back to the physician. These 124 recommendations can subsequently be discussed together with the patient [19, 20]. In the context 125 of FRIDs, a CDSS has the potential to support physicians through a structured deprescribing 126 approach by first signaling *which* medications pose a risk to the individual patient, and 127 subsequently advising how and when to safely deprescribe each medication (i.e., through 128 guideline integration). In turn, the decision to deprescribe certain medications can be discussed 129 together with the patient to foster joint medication management between physicians and patients. 130 Such shared decision-making has been shown to improve medication-related knowledge and 131 medication adherence in older patients, and could thus enhance the effectiveness of fall 132 preventive care in these patients [21].

Previous studies suggest that medication-related CDSS can improve care outcomes for older patients in a variety of contexts (e.g., inappropriate medication use by patients and polypharmacy, inappropriate prescribing by physicians, falls) [22-24]. However, these studies have not used the potential of a CDSS in deprescribing optimally, such as incorporating datadriven methods, like prediction models, in the system's clinical knowledge base [24]. Prediction

7

models combine data for multiple risk factors in order to calculate the risk of a future outcome,
and help inform subsequent decision making [25]. Thus, in the context of deprescribing
optimally, such models could serve as an adjunct to decision-making by allowing the physician
and patient to weigh the various treatment options on the basis of the patient's risk of falling
within 12 months. Moreover, such estimates of fall risk could help patients be more aware of
their risk of falling and as such motivate them to follow the advice recommended by the
physician.

145 Research suggests that the acceptance of CDSSs among physicians is still hindered by a 146 number of barriers, such as insufficient knowledge with system use, time-consuming, alert 147 fatigue and poor integration into workflow [24, 26-28]. A possible explanation for the 148 considerable number of usability barriers is the lack of involvement by physicians during the 149 development of these systems. A user-centered design approach is an iterative method that 150 involves end users of a system in each stage of the development process. Such an approach has 151 been found to enhance the ease of use and usefulness of clinical study tools – the two important 152 determinants that can influence technology adoption by healthcare professionals [29, 30].

153 The ADFICE_IT (Alerting on adverse **D**rug reactions: **F**alls prevention **I**mprovement 154 through developing a Computerized clinical support system: Effectiveness of Individualized 155 medicaTion withdrawal) project will develop and test a novel deprescribing intervention that 156 aims to prevent medication-related falls in older adults by means of a CDSS for physicians and 157 an online portal for patients. In doing so, it employs a user-centered design approach to develop a 158 data-driven CDSS that aims to provide optimal support for physicians during the deprescribing 159 of FRIDs by generating a personalized fall-risk estimate and guideline-based medication advice 160 tailored to the health conditions of each individual patient. The current paper aims to outline how

8

	User interface
	MRC Phase I: Development
178	Table 1. The development process of the CDSS for the ADFICE_IT intervention.
177	CDSS. An overview of the studies conducted in these phases is provided in Table 1.
176	interventions [31]. This paper summarizes the (I) development and (II) feasibility phases for our
175	theoretical framework for developing, pilot-testing, implementing and evaluating complex health
174	feasibility, (III) the implementation, and (IV) the evaluation phase. The MRC is a guiding
173	phases of the Medical Research Council framework (MRC): (I) the development, (II) the
172	The overall ADFICE_IT intervention is developed and evaluated following the four
171	Medical Research Council framework
170	participants gave written informed consent prior to data collection.
169	Medical Research Involving Human Subjects Act did not apply to this study. All study
168	(Amsterdam UMC, location University of Amsterdam; W19_310 # 19.368) declared that the
167	The Medical Ethics Research Committee of the Amsterdam University Medical Center
166	Ethics Statement
165	Materials and Methods
164	care setting later on.
163	development process to increase the system's acceptance and adoption in its intended clinical
162	showcase how end-users (i.e., the physicians) were successfully involved in each stage of the
161	end-user and expert insights were used to inform the development of our CDSS. We also

Dec. 1 2018 - July 15 2019

European survey: Barriers and facilitators in using a Clinical Decision Support System for fall risk management for older people [33]

9

Dec. 17 2019 – Jan. 3 2020	Semi-structured interviews: Physician
	needs for effective implementation and
	trustworthy decision making
2020	Scoping literature review: Risk
	communication needs of physicians
2020	Systematic literature review: Barriers and
	facilitators influencing medication-related
	CDSS acceptance according to clinicians
	[32]
Knowledge base	
Used latest edition 2017	Dutch fall guideline: Effect of medication
	on fall risk in older adults [36]
Feb. 5 2019 – Feb. 28 2020	Modified Delphi study: STOPPFall
	(Screening Tool of Older Persons
	Prescriptions in older adults with high fall
	risk): a Delphi study by the EuGMS Task
	and Finish Group on Fall-Risk-Increasing
	Drugs [34]
2020 - 2021	Logical elements rule method:
	Formalizing clinical rules for the CDSS
	[37]
Reasoning Engine and Software	
2021 - 2022	Agile methodology using test-driven
	development: Unit tests, acceptance tests,
	verification, and validation testing
Prediction model	

Prediction model

2020 - 2021	Development: The ADFICE_IT Models
	for Predicting Falls and Recurrent Falls in
	Community-Dwelling Older Adults:
	Pooled Analyses of European Cohorts
	With Special Attention to Medication [35]
MRC Phase II: Feasibility	
CDSS prototype 1	
Sept. 10 – 24 2020	Usability testing round 1: Identification of
	usability problems and adjustments to
	prototype
CDSS final version	
June 28 – July 18 2021	Usability testing round 2: Identification of
	remaining usability and development of
	final version

179 **Phase I: Development**

180 The aim of this phase was to cultivate a robust (theoretical) understanding about how to 181 develop the CDSS components of the ADFICE IT intervention [30], which consisted of the (1) 182 development of the user interface, (2) development of the clinical knowledge base, (3) 183 development of the prediction model, and (4) development of the software. A detailed 184 description of the methods for the systematic literature review, European online survey, modified 185 Delphi study, and development of the fall-risk prediction model have been published elsewhere 186 by the research team [32-35]. 187 **Development** of the user interface 188 To develop the user interface, a scoping and systematic literature review were carried out,

189 and extended with empirical research by means of a European online survey (n = 581), and semi-

190 structured interviews with physicians from Dutch fall clinics (n = 19). The scoping literature

11

191 review assessed the risk communication needs of physicians. The systematic literature review 192 assessed barriers and facilitators to CDSS use [32]. The latter barriers and facilitators to use 193 analysis was expanded on in the survey, which also examined relevant facilitators to use as 194 experienced by physicians [33]. Lastly, semi-structured interviews with physicians assessed the 195 needs for effective implementation and trustworthy decision making. For example, physicians 196 were asked *how* the system should communicate a patient's fall risk; or *how* the system can best 197 support physicians in making informed decisions about whether or not to deprescribe. The 198 analysis of these studies guided the development of the user interface of the CDSS, such as the 199 system's functionality, design, and content composition.

200 Development of the knowledge base

201 The STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high 202 fall risk) tool [34] and the Dutch fall guideline [36] were used to identify relevant FRIDs in 203 different medication classes. STOPPFall entails a FRIDs list with accompanying guidelines for 204 deprescribing, and was constructed using a modified Delphi technique through consensus effort 205 with 24 panelists from 13 European countries [34]. Both STOPPFall and the Dutch fall guideline 206 form the basis of the system's clinical knowledge base. To extend the knowledge base specific 207 deprescribing advice for each class of FRIDs was identified from over 30 guidelines, and 208 formalized using an adaptation of the Logical Elements Rule Method (LERM). LERM is a 209 validated method for formalizing clinical rules for decision support (e.g., a CDSS). The method 210 follows a step-by-step approach in which clinical rules are formulated by an informatics 211 knowledge expert, and close collaboration from a clinical expert is sought throughout rule 212 formalization to ensure that the intent of the guidelines are maintained [37]. Specifically, rather 213 than using conjunctive normal form as specified in LERM, the criteria for each rule were

12

formalized as medications to include (e.g., a class of FRIDs), medications to exclude (e.g., nonFRIDs within that class), and conditions (e.g. diagnoses or laboratory values that modify the
advice).

217 Development of the reasoning engine and software

218 Reasoning engine and software development followed an agile methodology, including 219 using test-driven development. Both unit tests (which test specific functions individually) and 220 acceptance tests (which test larger parts of the software as a whole) were used. The software was 221 developed in Node JS, using Express and MariaDB. Jest and TestCafe are used for testing [38-222 42]. For transparency, all software was developed as open-source software. Experienced 223 developers were involved in creating the software architecture and establishing the development 224 principles. Given the low expected load, clarity of code was prioritized over efficiency and 225 scalability. Importantly, good traceability between the specification for the knowledge base and 226 the implementation of these rules in the software was maintained throughout development, 227 including the provision of evidence behind the recommendations to the end user. 228 Verification and validation testing were also conducted. Regarding verification, test cases 229 (with specified input and expected output) were developed for each rule in the specification. If 230 any output was not as expected, the corresponding part of the logic was checked for errors and, if 231 needed, corrected. This was repeated until a 100% pass rate was achieved. These tests were 232 added to the test suite and are run every time a change is made to the software. Validation testing 233 took place in two rounds. First, fictional patient cases were constructed based on the 234 specification. Specifically, cases were designed such that each text that the CDSS can produce 235 appeared for at least one patient. The output was reviewed by NvdV to confirm that the advice 236 was clinically sound and reflected the intent of the underlying guidelines. Any identified

13

237	problems were corrected and the test was repeated. Second, informed consent was obtained from
238	10 patients and data from these patients was entered into the CDSS. NvdV and an expert in
239	geriatric pharmacy reviewed the cases and commented if they did not agree with the advice.
240	Since clinicians can have differing opinions on the same case, we aimed for 90% agreement with
241	these recommendations.
242	Development of the prediction model
243	To enable the generation of a patient's risk of falling within 12 months, a fall-risk
244	prediction model was developed by Van de Loo et al to fit the context of this study using a
245	harmonized dataset ($n = 5722$) of two Dutch cohorts and a German cohort study of community-
246	dwelling older adults (65+) [35]. This prediction model comprises a part of the CDSS's
247	knowledge base. For background, the outcome variable was defined as any fall (one or more
248	falls) within a one-year follow-up. Candidate predictors were selected based on previously
249	reported risk factors for falls that are easily obtained in clinical practice, such as
250	sociodemographic variables; measures of emotional, cognitive and physical functioning; self-
251	reported chronic conditions; variables related to lifestyle; biomarkers; and use of certain
252	medications. The prediction model was internally validated using an internal-external cross-
253	validation procedure, in which the performance of the model was tested in each of the
254	development cohorts separately following Steyerberg and Harrel [43].
255	Phase II: Feasibility
256	Usability testing of the CDSS prototype

The feasibility phase assessed whether the first prototype of the CDSS had any usability problems that needed to be fixed prior to developing the final version of the CDSS. This was achieved through usability testing with geriatric physicians (n = 5) from a Dutch academic

14

260	hospital. Each physician was presented with three hypothetical patient cases that varied in fall
261	risk (e.g., high versus low risk). Each physician completed at least one case. Next, physicians
262	were asked to carry out a scripted navigation consisting of realistic CDSS task scenarios,
263	resembling aspects of clinical documentation (e.g., analyzing a patient's fall-risk, selecting
264	relevant treatment options, making a referral). Throughout navigation, physicians were prompted
265	to "think aloud" and verbalize their thought process while carrying out the tasks (i.e. using a
266	concurrent think aloud method). Additionally, Camtasia 9, a usability software, was used to
267	record the screen and mouse movements of each physician, including facial expressions and
268	vocalizations (i.e., questions, expressions of confusion) [44].
269	Usability problems were identified for each physician session, and coded according to the
270	Nielsen usability problems severity rating ranging from $0 =$ "I don't agree that this is a usability
271	problem at all" to $4 =$ "Usability catastrophe: imperative to fix this before product can be
272	released" [45]. The categorization and potential negative impact of each identified usability
273	problem was assessed following the augmented scheme for classifying and prioritizing usability
274	problems [46]. Next, usability problems from all sessions were merged, and for each problem the
275	occurrence of that problem was noted. This led to an overview of usability problems ordered on
276	both severity and occurrence, ranging from the most severe and most often occurring problems
277	to the least severe and least occurring problems. The analysis of the results from this study led to
278	adjustments to the CDSS, resulting in a second version of the prototype. The aforementioned
279	procedure was repeated in a second usability study among six physicians. This allowed us to
280	pinpoint remaining usability issues that needed to be improved prior to the developing the final
281	version of the CDSS.
282	Results

15

283	The analysis of the results from all studies guided the development of the CDSS. In this
284	article, we report in detail the results of the scoping literature review, semi-structured interviews,
285	software development, and usability testing rounds. The results of the systematic literature
286	review, European online survey, modified Delphi study, and development of the fall-risk
287	prediction model are reported in detail elsewhere by the research team [32-35].

288 Phase I: Development

289 **Results from the scoping literature review**

290 Regarding the risk communication needs of physicians, the results suggest that physicians 291 prefer a holistic- and patient-specific approach to communicating health-related advice [26]. This 292 approach should include information that is actionable, directive and transparent [47-50]. When 293 visualizing risks, information-orientated graphs were perceived as easier to interpret by 294 physicians, and were found to enhance shared decision-making between physicians and patients 295 [49-51]. Similarly, using a traffic-light coloring system for the presentation of risk is believed to 296 facilitate information processing, which can lead to a more rapid assessment of risk-based 297 information by physicians [47, 49, 51]. Additionally, favorable effects were found on 298 information processing outcomes (e.g., enhanced attention, reduced cognitive load) when the 299 formatting of information and use of terminology was consistent, and when text density and 300 visual clutter was reduced [49, 50].

301

1 **Results from the semi-structured interviews**

Results showed that fall risk information should be displayed in color as either a number or percentage. With regard to effective patient-physician communication, a visual graph was viewed as beneficial for the patient, including the ability to print out a patient-friendly handout. This handout should include information about the patient's personalized fall risk and treatment

16

306	plan that was discussed during the consultation. Opportunities to read about the benefits and side
307	effects of deprescribing a medication, and having access to additional information (e.g., via
308	hyperlinks) were viewed as important in the decision making to deprescribe. Moreover,
309	information about how a patient's fall risk is calculated (i.e., the prediction model) was perceived
310	as vital information by physicians that would also enhance the system's credibility. Lastly, for
311	successful implementation of the CDSS in clinical practice, physicians stressed the importance
312	of reducing completion time (e.g., limiting the amount of mouse clicks).
313	Development of the user interface and knowledge base
314	Table 2 shows the hierarchical categorization of physicians aggregated system needs
315	from both literature reviews, the European online survey, and the semi-structured interviews with
316	physicians. These key requirements were subsequently operationalized into system features used
317	for the development of the user interface of the first CDSS prototype for usability testing.
318	Regarding the knowledge base of the system, the final set of clinical rules covering 22 classes of
319	FRIDs, with specific deprescribing advice based on diagnoses, lab values, and concurrent
320	medications, including the final fall-risk prediction model were integrated into the CDSS. The
321	final prediction model consisted of the following 14 predictors: educational status, depression,
322	body mass index, grip strength, gait speed, number of functional limitations, systolic blood
323	pressure, at least one fall in the previous 12 months, at least two falls in the previous 12 months,
324	fear of falling, smoking status, use of calcium channel blockers, use of antiepileptics, and use of
325	drugs for urinary frequency and incontinence (see Van de Loo et al. for detailed results) [35].

326 **Table 2. Hierarchical categorization of physicians aggregated needs.**

Key requirements for CDSS

R: Scoping literature review

S: Survey

	I: Semi-structured interviews
	1. Limit repeated and uninformative alerts (R/S).
	2. Include easy-to-use interactive features that cater towards physicians fast-paced work
	environment (R, I).
	3. Provide physicians with actionable recommendations on how a patient's fall risk can be
	reduced (R).
	4. Make information transparent and credible by including hyperlinks that direct physicians to
	information surrounding the fall-risk prediction model and other medication-related
	information (I).
	5. The CDSS should provide a holistic overview of the patient (e.g., comorbidities) (R).
	6. The format of the CDSS should be consistent (R).
	7. The presentation of risk should be presented in a text-format using concise and to-the-point
	language (e.g., using short sentences with standardized terminology) (R).
	8. Information should be presented in a systematic manner that complements the consultation
	workflow of physicians (R, S).
	9. A patient's fall risk should be accompanied with information-orientated graphs (e.g., bar
	graphs, icon arrays, pie-charts) (R, I).
	10. The information-orientated should employ a traffic-light coloring system (i.e., red for high
	risk, yellow for medium, risk, and green for no risk) (R, I).
	11. The CDSS should be efficient in use (i.e., fast completion time, limited clicks and text-
	entry fields) (I, S).
27	Development of the reasoning engine and software (prototype 1)
28	Following agile development principles, development of the software started by building
29	the smallest part that would be useful, which was the reasoning engine and an interface for
80	verification and validation testing that showed the advice text for the doctor, checkbox options,
31	corresponding patient-friendly text, and references all on one screen. Features were then added in
32	order of priority. This, in combination with test-driven development, lead to a modular
3	architecture with good separation between the connection to the Electronic Health Record

334 (EHR), the logic, and the user interface. This allowed developers to readily modify the interface

18

335 based on feedback received from phase II. Development as open source software facilitated 336 seeking and incorporating input from external expert developers. Regarding the system's 337 security, the software is designed to be hosted within the hospital network, and dependencies are 338 minimized to lower the security footprint and improve maintainability. Additionally, the CDSS 339 logic is kept server side to ensure that it cannot be changed from the browser, and that the 340 information seen by the user is always consistent with the saved data. Features were also added 341 to limit data being cached in the user's browser. Regarding verification and validation testing, 342 after verification testing and the first round of validation testing were completed with no 343 remaining errors detected, the second round of validation testing with real patient data was 344 conducted. This resulted in 100% agreement from one clinician and 95% agreement from the 345 other, which exceeded the minimum threshold of 90% agreement.

346 **Phase II: Feasibility**

347 **Results from usability testing rounds**

348 The first usability testing round (n = 5 physicians) identified 74 individual usability 349 problems with a mean Nielsen's severity rating classification of 2.49 (i.e., between minor to 350 major usability problems) [45]. Regarding major to severe usability problems, physicians 351 perceived difficulties with the general navigability of the system (e.g., no "back button") and the 352 medical terminology used within the system (e.g., what is meant by "lowest dose" or "minimal 353 effective dose" for deprescribing medications). These and similar usability problems were solved 354 and the CDSS underwent a second round of usability testing with 6 physicians. The number of 355 usability problems identified decreased by 16%, and the mean Nielsen's severity rating was 1.87 356 (i.e., between cosmetic to minor problems). The most pressing usability problems were improved 357 (e.g., fixing hyperlinks and task-orientated buttons), and the final version of the CDSS was

19

developed. After each usability testing round, the user interface and clinical knowledge base ofthe CDSS were further optimized, which led to the development of the final CDSS.

360 The final ADFICE_IT CDSS

361 The source code for the ADFICE IT software is available at https://github.com/adfice-it. 362 A connection between the EHR and the CDSS was made for the extraction of patient data into 363 the CDSS. This data is used to provide patient-specific advice and to calculate a patient's 364 personalized fall risk estimate. The final version of the CDSS is depicted in figures 1 through 5. 365 The CDSS consists of 5 web pages. Page 1 (titled "Start" in fig. 1) is the landing page of the 366 CDSS. On this page the physician can (1) check whether relevant patient information (e.g., age, 367 morbidities, list of medications) was correctly extracted from the EHR system, and add missing 368 data for calculating the fall risk estimate; (2) view a graphical representation of the patient's 369 personalized fall risk estimate by means of a gradient scale, and (3) view a model for shared 370 decision-making that can be implemented during the consultation. Additionally, physicians have 371 access to the patient identifier and personalized fall risk estimate during the entire consultation, 372 as this information is displayed in the form of a horizontal menu bar on all subsequent pages. 373 Page 2 (titled "Preparation" in fig. 2) lists each medication taken by the patient and 374 structurally provides the physician with patient-specific deprescribing advice for each listed 375 medication in an attempt to facilitate optimal deprescribing for the physician. Page 2 also 376 provides relevant non-medication related information for preventing falls in older patients (e.g., 377 referral to fall prevention interventions, leaflets, etc.). The clinician can select the treatment 378 options and/or non-medication related information they want to discuss with the patient. 379 Moreover, hyperlinks to third-party sources are provided for additional information about the

20

- 380 listed medications (i.e., "Farmacotherapeutisch Kompas") and related deprescribing advice (i.e.,
- 381 the guidelines used to formulate that advice).
- 382 Page 3 (titled "Consult" in fig. 3) provides an overview of the treatment options that the
- 383 physician selected to discuss together with the patient (i.e., the deprescribing advice or leaflets
- selected in page 2). Based on the discussion with the patient, a final treatment plan is determined.
- 385 Page 4 (titled "Advice" in fig. 4) displays the final treatment plan in a patient-friendly format,
- 386 which is printable by the physician and accessible by the patient via the patient portal. In page 5
- 387 (titled "Wrap-up" in fig. 5), the physician is able to copy a summary of the consultation into the
- 388 patient's EHR, for future storage.
- **Fig. 1. Start page of the ADFICE_IT CDSS.**
- 390 [Figure 1]
- **Fig. 2. Preparation page of the ADFICE_IT CDSS.**
- 392 [Figure 2]
- 393 Fig. 3. Consult page of the ADFICE_IT CDSS.
- 394 [Figure 3]
- **Fig. 4. Advice page of the ADFICE_IT CDSS.**
- 396 [Figure 4]
- 397 Fig. 5. Wrap-up page of the ADFICE_IT CDSS.
- 398 [Figure 5]
- 399 **Discussion**
- 400 This study outlined the user-centered development of a CDSS to support physicians in
- 401 the optimum deprescribing of FRIDs in older adults (65+). The system was developed for the
- 402 ADFICE_IT project, and intended for use in conjunction with a patient portal. In the

21

403 development phase (phase I), a robust theoretical understanding about key components of the 404 CDSS was cultivated. For this, both existing and new evidence was relied upon, in which 405 collaboration with end users of the system was sought throughout different stages of 406 development. In phase I, a fall-risk prediction model was developed and internally validated. 407 This prediction model was later integrated into the CDSS. Phase 1 also included the development 408 of the knowledge, reasoning engine and software. Moreover, verification and validation testing 409 were conducted to check for and subsequently correct errors relating to the generation of 410 deprescribing advice. Together, the results from phase I guided the development of the first 411 prototype of the CDSS. In the feasibility phase (phase II), two separate usability testing rounds 412 with geriatric physicians were conducted to identify and address remaining usability issues 413 within the CDSS that could hinder successful implementation of the system later on. 414 A key strength of this study was the ability to integrate the aggregated deprescribing 415 guidelines and the fall-risk prediction model into the clinical knowledge base of our CDSS. For 416 physicians, deprescribing FRIDs is an often complex task as differences in risk of adverse drug 417 events make it hard to determine whether reducing a particular FRID or combination of FRIDs 418 will result in a significant change in preventing a fall [12, 13]. According to Bloomfield et al., it 419 is exactly this particular complexity in FRIDs deprescribing that has not been effectively 420 addressed in past interventions [12]. This CDSS addresses this need by systematically guiding 421 physicians through the deprescribing of one or more FRIDs. The system does this by first 422 signaling a FRID from a patient's medication list, and subsequently leverages the stored 423 deprescribing guidelines to advise physicians on how the identified FRID can be deprescribed 424 optimally. Additionally, physicians can leverage the fall-risk prediction model as an adjunct to

22

425 decision-making by assessing different advice on the basis of the patient's estimated risk of426 falling within a 12-month period.

427 Another key strength of our study was implementing a user-centered design approach to 428 development. This, in our opinion, will greatly influence the acceptance of the system in its 429 intended clinical care setting, as its functionalities and content are tailored to the needs and 430 preferences of its primary end users. Past studies have shown low CDSS acceptance rates and a 431 high number of usability barriers when physicians are not involved in the development process 432 [24, 26-28]. Since the outcomes of the ADFICE IT intervention are dependent on physicians' 433 use of the CDSS, insights from the system's primary end users were gathered, namely physicians 434 treating older patients, at an early stage and throughout the development process of the system, 435 which led to several advantages. For example, the test-driven development allowed us to make 436 changes to the code with confidence that earlier added functionality was not being disrupted. 437 This also led to a more modular architecture within the code base, which facilitated making the 438 changes suggested by end users during the usability testing rounds. Additionally, while the 439 decision to favor clarity over performance aided in this process, it should be noted that this does 440 carry a limitation whereby the software – in its current form – is not scalable to support hundreds 441 of concurrent users. Moreover, future development could improve testing of the client software 442 further (e.g., unit and acceptance tests) by concentrating manipulation of the display to a few 443 parts of the web page, which could allow for easier testing during development. Lastly, while 444 employing a rigorous verification and validation process led to an improved version of the CDSS 445 after each feedback round, a limitation of this process was the involvement of one of the two 446 clinicians during earlier verification and validation steps. This may have resulted in higher

23

447 agreement, even though the system did perform well with the second clinician, who was not448 otherwise involved in the development process.

449	A final strength of our CDSS is that the system displays several different treatment
450	options (i.e., advice) for each identified FRID (i.e., using guideline-based reasoning), which
451	provides an opportunity for physicians to discuss preferred treatment options together with the
452	patient. This can foster joint medication management, which could help in tackling the observed
453	low rates of deprescribing compliance among patients [52]. In older patients, Van Weert et al.
454	showed that shared decision-making was effective at enhancing both medication-related
455	knowledge and adherence rates, which we believe could have a positive effect on the outcomes
456	of the ADFICE_IT intervention as well [21]. Specifically, the effectiveness of our CDSS (along
457	with the accompanying patient portal) are currently being tested in a multicenter, cluster-
458	randomized controlled trial with process evaluation in several Dutch hospitals.
459	Conclusions
460	This study followed a user-centered design approach to development to develop a CDSS
461	intended for use in fall clinics. The CDSS supports physicians in the optimum deprescribing of
462	FRIDs to prevent falls in older patients (65+), leveraging aggregated deprescribing guidelines, a
463	validated fall-risk prediction model, and shared decision-making. Moreover, due to the continued
464	involvement of end users, we were able to ensure that the CDSS was both useful and user-
465	friendly as each new feedback round led to an improved version of the system. The CDSS is
466	currently being tested in a multicenter, cluster-randomized controlled trial with process
467	evaluation at hospitals in the Netherlands.

468 Acknowledgments

24

- 469 The authors thank Tsvetan Yordanov, Rutger Bazen and Stephen Madson for their contributions
- 470 to the software, and Leonie Westerbeek for her contribution to the user interface. The authors
- 471 thank Eveline Poelgeest, Gerrit Jan Hafkamp, Irene Gomez Bruinewoud, Hester van der Kroon,
- 472 Hanna Willems, Suzanne Bleker, Oscar Smeekes and Stephanie van der Woude for their
- 473 contributions to testing the feasibility of the ADFICE_IT CDSS.

474 Availability of materials

- 475 Figure translations in English are available upon request from the corresponding author.
- 476 **References**
- 477 1. World Health Organization: Falls. <u>https://www.who.int/news-room/fact-sheets/detail/falls</u>
- 478 (2021). Accessed 25 Oct 2022.
- 479 2. Haagsma JA, Olij BF, Majdan M, van Beeck EF, Vos T, Castle CD, et al. Falls in older aged
- 480 adults in 22 European countries: incidence, mortality and burden of disease from 1990 to 2017.
- 481 Inj Prev. 2020;26(1):i67–74. <u>https://injuryprevention.bmj.com/content/26/Suppl_2/i67</u>
- 482 3. Hartholt KA, van Beeck EF, Polinder S, van der Velde N, van Lieshout EMM, Panneman
- 483 MJM, et al. Societal Consequences of Falls in the Older Population: Injuries, Healthcare Costs,
- 484 and Long-Term Reduced Quality of Life. J Trauma. 2011;71(3):748–53.
- 485 doi:10.1097/TA.0b013e3181f6f5e5
- 486 4. Peeters G, Bennett M, Donoghue OA, Kennelly S, Kenny RA. Understanding the aetiology of
- 487 fear of falling from the perspective of a fear-avoidance model A narrative review. Clin Psychol
- 488 Rev. 2020;79:101862. <u>https://doi.org/10.1016/j.cpr.2020.101862</u>
- 489 5. Petersen N, König H-H, Hajek A. The link between falls, social isolation and loneliness: A
- 490 systematic review. Arch Gerontol Geriatr. 2020;88:104020.
- 491 https://doi.org/10.1016/j.archger.2020.104020

25

- 492 6. Heinrich S, Rapp K, Rissmann U, Becker C, König HH. Cost of falls in old age: a systematic
- 493 review. Osteoporos Int. 2010 Jun 19;21(6):891–902.
- 494 <u>http://link.springer.com/10.1007/s00198-009-1100-1</u>
- 495 7. de Vries M, Seppala LJ, Daams JG, van de Glind EMM, Masud T, van der Velde N, et al.
- 496 Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: I. Cardiovascular Drugs. J
- 497 Am Med Dir Assoc. 2018;19(4):371.e1–9. <u>https://doi.org/10.1016/j.jamda.2017.12.013</u>
- 498 8. Seppala LJ, Wermelink AMAT, de Vries M, Ploegmakers KJ, van de Glind EMM, Daams JG,
- 499 et al. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: II. Psychotropics. J
- 500 Am Med Dir Assoc. 2018;19(4):371.e11–7. <u>https://doi.org/10.1016/j.jamda.2017.12.098</u>
- 501 9. Seppala LJ, van de Glind EMM, Daams JG, Ploegmakers KJ, de Vries M, Wermelink AMAT,
- 502 et al. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-analysis: III. Others. J Am
- 503 Med Dir Assoc. 2018;19(4):372.e1–8. <u>https://doi.org/10.1016/j.jamda.2017.12.099</u>
- 504 10. Michalcova J, Vasut K, Airaksinen M, Bielakova K. Inclusion of medication-related fall risk
- in fall risk assessment tool in geriatric care units. BMC Geriatr. 2020;20(1):1-11.
- 506 <u>https://doi.org/10.1186/s12877-020-01845-9</u>
- 507 11. Van der Velde N, Minhas JS. Appropriate deprescribing in older people: a challenging
- 508 necessity Commentary to accompany themed collection on deprescribing. Age Ageing.
- 509 2021;50(5):1516–9. <u>https://doi.org/10.1093/ageing/afab142</u>
- 510 12. Bloomfield HE, Greer N, Linsky AM, Bolduc J, Naidl T, Vardeny O, et al. Deprescribing for
- 511 Community-Dwelling Older Adults: a Systematic Review and Meta-analysis. J Gen Intern Med.
- 512 2020;35(11):3323–32. https://doi.org/10.1007/s11606-020-06089-2

- 513 13. Lee J, Negm A, Peters R, Wong EKC, Holbrook A. Deprescribing fall-risk increasing drugs
- 514 (FRIDs) for the prevention of falls and fall-related complications: a systematic review and meta-
- 515 analysis. BMJ Open. 2021;11(2):e035978. doi:10.1136/bmjopen-2019-035978
- 516 14. Bell HT, Steinsbekk A, Granas AG. Factors influencing prescribing of fall-risk-increasing
- 517 drugs to the elderly: A qualitative study. Scand J Prim Health Care. 2015;33(2):107–14.
- 518 https://doi.org/10.3109/02813432.2015.1041829
- 519 15. Tinetti ME, Gordon C, Sogolow E, Lapin P, Bradley EH. Fall-Risk Evaluation and
- 520 Management: Challenges in Adopting Geriatric Care Practices. Gerontologist. 2006;46(6):717–
- 521 25. <u>https://doi.org/10.1093/geront/46.6.717</u>
- 522 16. Drickamer MA, Levy B, Irwin KS, Rohrbaugh RM. Perceived needs for geriatric education
- 523 by medical students, internal medicine residents and faculty. J General Intern Med.
- 524 2006;21:1230-4.
- 525 17. Hoffmann TC, Del Mar C. Clinicians' expectations of the benefits and harms of treatments,
- 526 screening, and tests: a systematic review. JAMA Intern Med. 2017;177:407–19.
- 527 doi:10.1001/jamainternmed.2016.8254
- 528 18. Laing SS, Silver IF, York S, Phelan EA. Fall Prevention Knowledge, Attitude, and Practices
- 529 of Community Stakeholders and Older Adults. J Aging Res. 2011;2011:1–9.
- 530 doi:10.4061/2011/395357
- 531 19. Goud R, van Engen-Verheul M, de Keizer NF, Bal R, Hasman A, Hellemans IM, et al. The
- 532 effect of computerized decision support on barriers to guideline implementation: A qualitative
- 533 study in outpatient cardiac rehabilitation. Int J Med Inform. 2010;79(6):430–7.
- 534 <u>https://doi.org/10.1016/j.ijmedinf.2010.03.001</u>

- 535 20. Sim I, Gorman P, Greenes RA, Haynes RB, Kaplan B, Lehmann H, et al. Clinical Decision
- 536 Support Systems for the Practice of Evidence-based Medicine. J Am Med Inform Assoc.
- 537 2001;8(6):527–34. <u>https://doi.org/10.1136/jamia.2001.0080527</u>
- 538 21. Van Weert JCM, van Munster BC, Sanders R, Spijker R, Hooft L, Jansen J. Decision aids to
- help older people make health decisions: a systematic review and meta-analysis.
- 540 BMC Med Inform Decis Mak. 2016;16(1):1-20. doi:10.1186/s12911-016-0281-8
- 541 22. Clyne B, Bradley MC, Hughes C, Fahey T, Lapane KL. Electronic Prescribing and Other
- 542 Forms of Technology to Reduce Inappropriate Medication Use and Polypharmacy in Older
- 543 People: A Review of Current Evidence.
- 544 Clin Geriatr Med. 2012;28(2):301–22. <u>https://doi.org/10.1016/j.cger.2012.01.009</u>
- 545 23. Dalton K, O'Brien G, O'Mahony D, Byrne S. Computerised interventions designed to reduce
- 546 potentially inappropriate prescribing in hospitalised older adults: a systematic review and meta-
- 547 analysis. Age Ageing. 2018;47(5):670–8. <u>https://doi.org/10.1093/ageing/afy086</u>
- 548 24. Damoiseaux-Volman B, van der Velde N, Ruige S, Romijn J, Abu-Hanna A, Medlock
- 549 SEffect of Interventions With a Clinical Decision Support System for Hospitalized Older
- 550 Patients: Systematic Review Mapping Implementation and Design Factors
- 551 JMIR Med Inform 2021;9(7):e28023. doi:10.2196/28023
- 552 25. Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al.
- 553 Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis
- 554 (TRIPOD): Explanation and Elaboration. Ann Intern Med. 2015;162(1):W1.
- 555 26. Kilsdonk E, Peute LW, Jaspers MWM. Factors influencing implementation success of
- 556 guideline-based clinical decision support systems: A systematic review and gaps analysis. Int J
- 557 Med Inform. 2017;98:56–64. <u>https://doi.org/10.1016/j.ijmedinf.2016.12.001</u>

- 558 27. Moxey A, Robertson J, Newby D, Hains I, Williamson M, Pearson S-A. Computerized
- 559 clinical decision support for prescribing: provision does not guarantee uptake. J Am Med Inform
- 560 Assoc. 2010;17(1):25–33. <u>https://doi.org/10.1197/jamia.M3170</u>
- 561 28. Trinkley KE, Blakeslee WW, Matlock DD, Kao DP, Van Matre AG, Harrison R, et al.
- 562 Clinician preferences for computerised clinical decision support for medications in primary care:
- a focus group study. BMJ Health Care Inform. 2019;26(1):e000015. doi:10.1136/bmjhci-2019-
- 564 000015
- 565 29. Gagnon M-P, Desmartis M, Labrecque M, Car J, Pagliari C, Pluye P, et al. Systematic
- 566 Review of Factors Influencing the Adoption of Information and Communication Technologies
- 567 by Healthcare Professionals. J Med Syst. 2010;36(1):241–77.
- 568 https://doi.org/10.1007/s10916-010-9473-4
- 569 30. Walden A, Garvin L, Smerek M, Johnson C. User-centered design principles in the
- 570 development of clinical research tools. Clin Trials. 2020;17(6):703–11.
- 571 https://doi.org/10.1177/1740774520946314
- 572 31. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and
- 573 evaluating complex interventions: the new Medical Research Council guidance. Int J
- 574 Nurs Stud. 2013;50(5), 587-92. <u>https://doi.org/10.1016/j.ijnurstu.2012.09.010</u>
- 575 32. Westerbeek L, Ploegmakers KJ, De Bruijn GJ, Linn AJ, Van Weert JCM, Daams JG, et al.
- 576 Barriers and facilitators influencing medication-related CDSS acceptance according to clinicians:
- 577 A systematic review. Int J Med Inform. 202;152:104506.
- 578 https://doi.org/10.1016/j.ijmedinf.2021.104506

- 579 33. Ploegmakers KJ, Medlock S, Linn AJ, Lin Y, Seppala LJ, Petrovic M, et al. Barriers and
- 580 facilitators in using a Clinical Decision Support System for fall risk management for older
- 581 people: a European survey. Eur Geriatr Med. 2022; 13, 395–405.
- 582 <u>https://doi.org/10.1007/s41999-021-00599-w</u>
- 583 34. Seppala LJ, Petrovic M, Ryg J, Bahat G, Topinkova E, Szczerbińska K, et al. STOPPFall
- 584 (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study
- 585 by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Age Ageing.
- 586 2021;50(4):1189–99. https://doi.org/10.1093/ageing/afaa249
- 587 35. Van de Loo B, Seppala LJ, van der Velde N, Medlock S, Denkinger M, de Groot LCPGM, et
- al. Development of the ADFICE_IT models for predicting falls and recurrent falls in community-
- 589 dwelling older adults: pooled analyses of European cohorts with special attention to medication.
- 590 J Gerontol A Biol Sci Med Sci. 2022;77(7):1446-54. <u>https://doi.org/10.1093/gerona/glac080</u>
- 591 36. Richtlijnendatabase. Effect medicijnen op valrisico ouderen Richtlijn. 2017.
- 592 https://richtlijnendatabase.nl/richtlijn/preventie_van_valincidenten_bij_ouderen/effect_medicijne
- 593 <u>n_op_valrisico_ouderen.html</u>. Accessed 26 Oct 2022.
- 594 37. Medlock S, Opondo D, Eslami S, Askari M, Wierenga P, de Rooij SE, et al. LERM (Logical
- 595 Elements Rule Method): A method for assessing and formalizing clinical rules for
- 596 decision support. Int J Med Inform. 2011;80(4):286–95.
- 597 <u>http://dx.doi.org/10.1016/j.ijmedinf.2011.01.014</u>
- 598 38. Node.js Foundation. Node.js. 2019. <u>https://nodejs.org/en/</u>. Accessed 26 Oct 2022.
- 599 39. Express. Fast, unopinionated, minimalist web framework for Node.js. Expressjs.com. 2017.
- 600 <u>http://expressjs.com/</u>. Accessed 26 Oct 2022.

- 40. MariaDB Foundation. MariaDB server: The open source relational database. MariaDB.org.
- 602 2015. <u>https://mariadb.org/</u>. Accessed 26 Oct 2022.
- 41. Jest. Delightful JavaScript Testing. Jestjs.io. 2017. <u>https://jestjs.io/</u>. Accessed 26 Oct 2022.
- 42. TestCafe. End-to-end testing, simplified. testcafe.io. <u>https://testcafe.io/</u>. Accessed 26 Oct
- 605 2022.
- 606 43. Steyerberg EW, Harrell FE. Prediction models need appropriate internal, internal–external,
- and external validation. J Clin Epidemiol. 2016;69:245–7.
- 608 https://doi.org/10.1016/j.jclinepi.2015.04.005
- 609 44. TechSmith Camtasia. Screen Recorder & Video Editor. TechSmith. 2022.
- 610 <u>https://www.techsmith.com/video-editor.html</u>. Accessed 26 Oct 2022.
- 611 45. Nielsen J. Usability engineering. Boston: Academic Press; 1993.
- 612 46. Khajouei R, Peute LWP, Hasman A, Jaspers MWM. Classification and prioritization of
- 613 usability problems using an augmented classification scheme. J Biomed Inform. 2011;44(6):948–
- 614 57. https://doi.org/10.1016/j.jbi.2011.07.002
- 615 47. Kennedy G, Gallego B. Clinical prediction rules: A systematic review of healthcare provider
- opinions and preferences. Int J Med Inform. 2019;123:1–10.
- 617 <u>https://doi.org/10.1016/j.ijmedinf.2018.12.003</u>
- 618 48. Khong PCB, Holroyd E, Wang W. A critical review of the theoretical frameworks and the
- 619 conceptual factors in the adoption of clinical decision support systems. Comput Inform Nurs.
- 620 2015;33(12): 555-70. doi:10.1097/CIN.000000000000196
- 621 49. Leichtling G, Hildebran C, Novak K, Alley L, Doyle S, Reilly C, et al. Physician Responses
- to Enhanced Prescription Drug Monitoring Program Profiles. Pain Med. 2019;21(2):e9–21.
- 623 <u>https://doi.org/10.1093/pm/pny291</u>

- 624 50. Miller K, Mosby D, Capan M, Kowalski R, Ratwani R, Noaiseh Y, et al. Interface,
- 625 information, interaction: a narrative review of design and functional requirements for clinical
- 626 decision support. JAMIA. 2018;25(5):585–92. <u>https://doi.org/10.1093/jamia/ocx118</u>
- 627 51. Van Maurik IS, Visser LN, Pel-Littel RE, Buchem MM van, Zwan MD, Kunneman M, et al.
- 628 Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and
- 629 Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease. JMIR Form
- 630 Res. 2019;3(3):e13417. doi:10.2196/13417
- 631 52. Boyé NDA, van der Velde N, de Vries OJ, van Lieshout EMM, Hartholt KA, Mattace-Raso
- FUS, et al. Effectiveness of medication withdrawal in older fallers: results from the Improving
- 633 Medication Prescribing to reduce Risk Of FALLs (IMPROveFALL) trial. Age Ageing.
- 634 2017;46(1):142-6. <u>https://doi.org/10.1093/ageing/afw161</u>